Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
205.6 SEK | -0.29% |
|
0.00% | +61.76% |
Jul. 05 | European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading | MT |
Jul. 05 | Calliditas Therapeutics' Partner Launches Japanese Trial for IgA Nephropathy Treatment | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 73.56 and 10.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+61.76% | 1.06B | C | ||
+5.90% | 71.83B | A | ||
+22.78% | 9.56B | A- | ||
+30.09% | 4.85B | B- | ||
-21.31% | 4.48B | A- | ||
+24.78% | 3.9B | - | ||
+11.03% | 2.01B | - | - | |
-2.11% | 1.99B | B | ||
-36.28% | 1.89B | C- | ||
-43.19% | 1.77B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CALTX Stock
- Ratings Calliditas Therapeutics AB